Lymphopenia is a condition in which there is a lower-than-normal number of lymphocytes (a type of white blood cell) in the blood. Also called lymphocytic leukopenia and lymphocytopenia.
Thus, the need to stratify the risk of severe or critical disease in patients presenting with SARS-CoV-2 infection remains a crying necessity. A new preprint research paper posted to the medRxiv server discusses the relationship between severe disease and pre-existing susceptibility to clots and other diseases of the cardiovascular system.
Patients with cancer have a more challenging time with infections while undergoing treatment — placing them as high-risk for severe COVID-19 illness and death. However, how the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) interacts with cancer therapies remains poorly understood.
Transplant patients are typically on chronic immunosuppression, making them automatically more vulnerable to infection with SARS-CoV-2, the agent responsible for the loss of over three million lives in the current COVID-19 pandemic. A new study discusses evidence for subnormal immune responses following COVID-19 in this population.
A new study shows that the immunological features of severe COVID-19 are already present in healthy older adults and in men, before they are infected, indicating a possible explanation for this differential susceptibility towards the virus.
Against the background of the COVID-19 pandemic, the impact of SARS-CoV-2 infection in pregnancy has been a subject of much controversy. In order to help answer the question as to whether this infection causes significant harm in pregnancy, a new study, released as a medRxiv* preprint, reports on the disease outcomes of this infection in pregnant women.
An interesting new study discusses how adaptive cellular immunity against the SARS-CoV-2 is dependent on differences in HLA-encoding genes between patients.
A new study describes a synthetic peptide used as a platform to generate protective adaptive cellular immunity to the virus in rhesus macaques, which are the gold standard for preclinical testing in humans.
A team of scientists from the United States has recently compared the immune response elicited by natural severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) vaccination. Their findings reveal that, unlike vaccination, natural SARS-CoV-2 infection is associated with a robust interferon response together with an induction of cytotoxic gene expression in peripheral blood lymphocytes. The study is currently available on the medRxiv* preprint server.
A new research paper posted to the medRxiv* preprint server describes the changes in genomic sequence observed during the course of infection in a patient on the drug tacrolimus, along with steroids, both potent immunosuppressants, and who also received convalescent plasma treatment. These mutations were observed to occur within three weeks from infection.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive-sense single-stranded RNA virus that is contagious in humans. It is the causal agent of the ongoing coronavirus 2019 (COVID-19) pandemic. This virus causes a mild to severe infection and has claimed over 2.95 million lives worldwide. SARS-CoV-2 is the successor to SARS-CoV-1, the virus that caused the 2002–2004 SARS outbreak.
The gut is a well-established route of infection and target for viral damage by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent for COVID-19. This is supported by the clinical observation that about half of COVID-19 patients exhibit gastrointestinal (GI) symptoms.
In the study, which appeared on the pre-print server medRxiv, the team found that when the monkeys were reinfected, the T cell-depleted animals showed anamnestic immune responses, the enhanced reaction of the body's immune system to an antigen that is related to an antigen previously encountered.
The COVID-19 pandemic has claimed over 2.67 million lives in less than a year and a half. However, it is uncommon in children, with less than 2% of the cases being in individuals below the age of 19. Most of these are of mild severity, with the clinical features of severe COVID-19 being rare in this age group.
The ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread to over 192 countries and territories, causing an enormous loss of lives and economic devastation.
A team of researchers from the CHUM Research Centre has identified new biomarkers associated with the severity of COVID-19 in infected patients.
A team of researchers at Georgetown University Medical Center, USA, investigated how SARS-CoV-2 affects the immune system’s response during and after infection and contributes to the severity of COVID-19.
While primarily a respiratory illness, there are distinctive alterations in the type and number of blood cells in COVID-19. A new study by a team of researchers in Germany describes the nature of these changes.
To discriminate between patients with severe and non-severe COVID-19 quickly, researchers from Peru looked for prognostic signatures in the blood samples of COVID-19 patients. Virgilio E. Failoc-Rojas et al. examined laboratory results and clinical prognosis of COVID-19 patients from a hospital in the Peruvian Amazon.
Researchers at the University of California, Irvine set out to determine the differences between young people and older adults regarding their host responses against SARS-CoV-2. The team revealed that independent of disease severity, COVID-19 was linked to a significant shift in plasma inflammatory factors. The research is posted to the pre-print server medRxiv*.
A recent US study, currently available on medRxiv preprint server, supports a beneficial rather than immunopathologic role for effector T-cells during serious infections with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) –